Tissue-provider AlloSource said this week it completed production of investigational bioengineered blood vessels designed for Humacyte‘s Phase III clinical trial exploring the use of the vessels to improve vascular access for hemodialysis patients with end-stage renal failure. The trail aims to compare the efficacy of the bioengineered human-tissue vessels to current synthetic vessels made from […]